My watch list  

Essential fatty acid interactions

The actions of the ω-3 and ω-6 essential fatty acids (EFAs) are best characterized by their interactions; they cannot be understood separately.

For introductory details to this topic, including terminology and ω-3 / ω-6 nomenclature, see the main articles at Essential fatty acid and Eicosanoid.

Arachidonic acid (AA) is a 20-carbon ω-6 essential fatty acid. [1] It sits at the head of the "arachidonic acid cascade" – more than twenty different signalling paths that control a wide array of bodily functions, but especially those functions involving inflammation and the central nervous system.[2] Most AA in the human body derives from dietary linoleic acid (another essential fatty acid, 18:2 ω-6), which comes both from vegetable oils and animal fats.

In the inflammatory response, two other groups of dietary essential fatty acids form cascades that parallel and compete with the arachidonic acid cascade. EPA (20:5 ω-3) provides the most important competing cascade. It is ingested from oily fish or derived from dietary a linolenic acid found in e.g., flax oil. DGLA (20:3 ω-6) provides a third, less prominent cascade. It derives from dietary GLA (18:3 ω-6) found in, e.g. borage oil. These two parallel cascades soften the inflammatory effects of AA and its products. Low dietary intake of these less inflammatory essential fatty acids, especially the ω-3s, is associated with a variety of inflammation-related diseases.

Today, the usual diet in industrial countries contains much less ω-3 fatty acids than the diet of a century ago. The diet from a century ago had much less ω-3 than the diet of early hunter-gatherers, [3]. We can also look at the ratio of ω-3 to ω-6 in comparisons of their diets. These changes have been accompanied by increased rates of many diseases – the so-called diseases of civilization – that involve inflammatory processes. There is now very strong evidence [4] that several of these diseases are ameliorated by increasing dietary ω-3, and good evidence for many others. There is also more preliminary evidence showing that dietary ω-3 can ease symptoms in several psychiatric disorders.[5]


Eicosanoid series nomenclature

For details on the metabolic pathways for eicosanoids in each series, see the main articles for prostaglandins (PG), thromboxanes (TX), prostacyclins (PGI) and leukotrienes (LK).

Eicosanoids are signalling molecules derived from the EFAs; they are a major pathway by which the EFAs act in the body. There are four classes of eicosanoid and two or three series within each class. Before discussing eicosanoid action, we will explain the series nomenclature.

Cell's outer membranes contain phospholipid fat. Each phospholipid molecule contains two fatty acids. Some of these fatty acids are 20-carbon polyunsaturated essential fatty acids – AA, EPA or DGLA. In response to a variety of inflammatory signals, these EFAs are cleaved out of the phospholipid and released as free fatty acids. Next, the EFA is oxygenated (by either of two pathways), then further modified, yielding the eicosanoids. [6]   Cyclooxygenase (COX) oxidation removes two C=C double bonds, leading to the TX, PG and PGI series. Lipoxygenase oxidation removes no C=C double bonds, and leads to the LK. [7]

After oxidation, the eicosanoids are further modified, making a series. Members of a series are differentiated by an ABC... letter, and are numbered by the number of double bonds, which does not change within a series. For example, cyclooxygenase action upon AA (with 4 double bonds) leads to the series-2 thromboxanes (TXA2, TXB2... ) each with two double bonds. Cyclooxygenase action on EPA (with 5 double bonds) leads to the series-3 thromboxanes (TXA3, TXB3... ) each with three double bonds. There are exceptions to this pattern, some of which indicate stereochemistry (PGF).

Figure (1) shows these sequences for AA (20:4 ω-6). The sequences for EPA (20:5 ω-3) and DGLA (20:3 ω-6) are analogous.
Table (1) Three 20-carbon EFAs and the eicosanoid series derived from them
Essential Fatty Acid
Abbr Formula
ω carbons:double bonds
Eicosanoid product series
LK Effects
Gamma-linolenic acid
   via Dihomo gamma linolenic acid
ω-6 18:3
ω-6 20:3
series-1 series-3 less inflammatory
Arachidonic acid AA ω-6 20:4 series-2 series-4 more inflammatory
Eicosapentaenoic acid EPA ω-3 20:5 series-3 series-5 less inflammatory

All the prostenoids are substituted prostanoic acids. Cyberlipid Center's Prostenoid page[8] illustrates the parent compound and the rings associated with each series–letter.

The IUPAC and the IUBMB use the equivalent term Icosanoid.[7]

Arachidonic acid cascade in inflammation

  In the arachidonic acid cascade, dietary linoleic acid (18:2 ω-6) is lengthened and desaturated to form arachidonic acid, esterified into the phospholipid fats in the cell membrane. Next, in response to many inflammatory stimuli, phospholipase is generated and cleaves this fat, releasing AA as a free fatty acid. AA can then be oxygenated and then further modified to form eicosanoids – autocrine and paracrine agents that bind receptors on the cell or its neighbors. Alternatively, AA can diffuse into the cell nucleus and interact with transcription factors to control DNA transcription for cytokines or other hormones.

Mechanisms of ω-3 eicosanoid action

  The eicosanoids from AA generally promote inflammation. Those from GLA (via DGLA) and from EPA are generally less inflammatory, or inactive, or even anti-inflammatory. (This generalization is qualified: an eicosanoid may be pro-inflammatory in one tissue and anti-inflammatory in another. See discussion of PGE2 at Calder[9] or Tilley.[10])

Figure (2) shows the ω-3 and -6 synthesis chains, along with the major eicosanoids from AA, EPA and DGLA.

Dietary ω-3 and GLA counter the inflammatory effects of AA's eicosanoids in three ways – displacement, competitive inhibition and direct counteraction.


Dietary ω-3 decreases tissue concentrations of AA. Animal studies show that increased dietary ω-3 results in decreased AA in brain and other tissue, [11]. Linolenic acid (18:3 ω-3) contributes to this by displacing linoleic acid (18:2 ω-6) from the elongase and desaturase enzymes that produce AA. EPA inhibits phospholipase A2's release of AA from cell membrane.[12]   Other mechanisms involving the transport of EFAs may also play a role.

The reverse is also true – high dietary linoleic acid decreases the body's conversion of α-linolenic acid to EPA. However, the effect is not as strong; the desaturase has a higher affinity for α-linolenic acid than it has for linoleic acid, [13].

Competitive Inhibition

DGLA and EPA compete with AA for access to the cyclooxygenase and lipoxygenase enzymes. So the presence of DGLA and EPA in tissues lowers the output of AA's eicosanoids. For example, dietary GLA increases tissue DGLA and lowers TXB2. [14] [15] Likewise, EPA inhibits the production of series-2 PG and TX. [9] Although DGLA forms no LTs, a DGLA derivative blocks the transformation of AA to LTs. [16]


Some DGLA and EPA derived eicosanoids counteract their AA derived counterparts. For example, DGLA yields PGE1, which powerfully counteracts PGE2. [17]   EPA yields the antiaggregatory prostacyclin PGI3 [18] It also yields the leuokotriene LTB5 which vitiates the action of the AA-derived LTB4. [19]

The paradox of dietary GLA

Dietary linoleic acid (LA, 18:2 ω-6) is inflammatory. In the body, LA is desaturated to form GLA (18:3 ω-6), yet dietary GLA is anti-inflammatory. Some observations partially explain this paradox: LA competes with α-linolenic acid, (ALA, 18:3 ω-3) for Δ6-desaturase, and thereby eventually inhibits formation of anti-inflammatory EPA (20:5 ω-3). In contrast, GLA does not compete for Δ6-desaturase. GLA's elongation product DGLA (20:3 ω-6) competes with 20:4 ω-3 for the Δ5-desaturase, and it might be expected that this would make GLA inflammatory, but it is not, perhaps because this step isn't rate-determining. Δ6-desaturase does appear to be the rate-limiting step; 20:4 ω-3 does not significantly accumulate in bodily lipids.

DGLA inhibits inflammation through both competitive inhibition and direct counteraction (see above.) Dietary GLA leads to sharply increased DGLA in the white blood cells' membranes, where LA does not. This may reflect white blood cells' lack of desaturase.Supplementing dietary GLA increases serum DGLA without increasing serum AA.[20] [17]

It is likely that some dietary GLA eventually forms AA and contributes to inflammation. Animal studies indicate the effect is small.[15] The empirical observation of GLA's actual effects argues that DGLA's anti-inflammatory effects dominate.[21]

Complexity of pathways

Eicosanoid signaling paths are complex. It is therefore difficult to characterize the action any particular eicosanoid. For example, PGE2 binds four receptors, dubbed EP1–4. Each is coded by a separate gene, and some exist in multiple isoforms. Each EP receptor in turn couples to a G protein. The EP2, EP4 and one isoform of the EP3 receptors couple to Gs. This increases intracellular cAMP and is anti-inflammatory. EP1 and other EP3 isoforms couple to Gq. This leads to increased intracellular calcium and is pro-inflammatory. Finally, yet another EP3 isoform couples to Gi, which both decreases cAMP and increases calcium. Many immune-system cells express multiple receptors that couple these apparently opposing pathways.[10] Presumably, EPA-derived PGE3 has a somewhat different effect of on this system, but it is not well-characterized.

The arachidonic acid cascade in the central nervous system (CNS)

The arachidonic acid cascade is arguably the most elaborate signaling system neurobiologists have to deal with.

—Daniele Piomelli, Arachidonic Acid[2]

The arachidonic acid cascade proceeds somewhat differently in the brain. Neurohormones, neuromodulators or neurotransmitters act as first messengers. They activate phospholipidase to release AA from neuron cell membranes as a free fatty acid. During its short lifespan, free AA may affect the activity of the neuron's ion channels and protein kinases. Or it may be metabolized to form eicosanoids, epoxyeicosatrienoic acids (EETs), neuroprotectin D or various endocannabinoids (anandamide and its analogs.)

The actions of eicosanoids within the brain are not as well characterized as they are in inflammation. It is theorized that they act within the neuron as second messengers controlling presynaptic inhibition and the activation of protein kinase C. They also act as paracrine mediators, acting across synapses to nearby cells. Although detail on the effects of these signals is scant, (Piomelli, 2000) comments

Neurons in the CNS are organized as interconnected groups of functionally related cells (e.g., in sensory systems). A diffusible factor released from a neuron into the interstitial fluid, and able to interact with membrane receptors on adjacent cells, would be ideally used to "synchronize" the activity of an ensemble of interconnected neural cells. Furthermore, during development and in certain forms of learning, postsynaptic cells may secrete regulatory factors which diffuse back to the presynaptic component, determining its survival as an active terminal, the amplitude of its sprouting, and its efficacy in secreting neurotransmitters—a phenomenon known as retrograde regulation. The participation of arachidonic acid metabolites in retrograde signaling and in other forms of local modulation of neuronal activity has been proposed.
Table (2) The arachidonic acid cascades act differently between the inflammatory response and the brain.
Arachidonic Acid Cascade
  In inflammation In the brain
Major effect on Inflammation in tissue Neuronal excitability
AA released from White blood cells Neurons
Triggers for AA release Inflammatory stimuli Neurotransmitters, neurohormones
and neuromodulators
Intracellular effects on DNA transcription of cytokines and other
mediators of inflammation
Activity of ion channels and protein
Metabolized to form Eicosanoids, resolvins, isofurans, isoprostanes,
lipoxins, epoxyeicosatrienoic acids (EETs)
Eicosanoids, neuroprotectin D, EETs
and some endocannabinoids

The EPA and DGLA cascades are also present in the brain and their eicosanoid metabolites have been detected. The ways in which these differently affect mental and neural processes are not nearly as well characterized as are the effects in inflammation.

Further Discussion

Figure (2) shows one pathway from EPA to DHA; for an alternative, see Sprecher's shunt.

5-LO acts at the fifth carbon from the carboxyl group. Other lipoxygenases—8-LO, 12-LO and 15-LO—make other eicosanoid-like products. To act, 5-LO uses the nuclear-membrane enzyme 5-lipoxygenase-activating protein (FLAP), first to a hydroperoxyeicosatetraenoic acid (HPETE), then to the first leuokotriene, LTA.

See also


  1. ^ Cunnane, Stephen C (June, 2005). Essential Fatty Acids: Time for a New Paradigm?. PUFA Newsletter. Retrieved on 2006-03-14.
  2. ^ a b Piomelli, Daniele (2000). Arachidonic Acid. Neuropsychopharmacology: The Fifth Generation of Progress. Retrieved on 2006-03-03.
  3. ^ Simopoulos A (2001). "Evolutionary aspects of diet and essential fatty acids". World Rev Nutr Diet 88: 18-27. PMID 11935953.
  4. ^ National Institute of Health (August 1, 2005). Omega-3 fatty acids, fish oil, alpha-linolenic acid. Retrieved on March 26, 2006.
  5. ^ De Caterina, R and Basta, G. n-3 Fatty acids and the inflammatory response – biological background. Retrieved on June 1, 2006.
  6. ^ Dorlands Medical Dictionary entry for 'Prostaglandin'. Retrieved on October 23, 2005.
  7. ^ a b Cyberlipid Center. Polyenoic fatty acids. Retrieved on February 11, 2006.
  8. ^ Cyberlipid Center. Prostanoids. Retrieved on February 11, 2006.
  9. ^ a b Calder, Philip C. (September 2004). n-3 Fatty Acids and Inflammation – New Twists in an Old Tale. Retrieved on February 8, 2006.
    • Invited review article, PUFA Newsletter.
  10. ^ a b Tilley S, Coffman T, Koller B (2001). "Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes". J Clin Invest 108 (1): 15-23. PMID 11435451. Retrieved on 2007-01-30.
  11. ^ Medical Study News (25-May-2005). Brain fatty acid levels linked to depression. Retrieved on February 10, 2006.
    • Who were in turn citing Pnina Green, Iris Gispan-Herman and Gal Yadid (June 2005). Increased arachidonic acid concentration in the brain of Flinders Sensitive Line rats, an animal model of depression. Retrieved on February 10, 2006.
  12. ^ KP Su, SY Huang, CC Chiu, WW Shen (2003). Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled ?. Retrieved on February 22, 2006.
  13. ^ Phinney, SD , RS Odin, SB Johnson and RT Holman (1990). "Reduced arachidonate in serum phospholipids and cholesteryl esters associated with vegetarian diets in humans". American Journal of Clinical Nutrition 51: 385-392. Retrieved on February 11, 2006.
    • "[D]ietary arachidonic acid enriches its circulating pool in humans; however, 20:5n-3 is not similarly responsive to dietary restriction."
  14. ^ Guivernau M, Meza N, Barja P, Roman O. (Nov 1994). Clinical and experimental study on the long-term effect of dietary gamma-linolenic acid on plasma lipids, platelet aggregation, thromboxane formation, and prostacyclin production.. Retrieved on 4 February, 2005.
    • GLA decreases triglycerides, LDL, increases HDL, decreases TXB2 and other inflammatory markers. Review article; human and rat studies.
  15. ^ a b Karlstad MD, DeMichele SJ, Leathem WD, Peterson MB. (Nov 1993). Effect of intravenous lipid emulsions enriched with gamma-linolenic acid on plasma n-6 fatty acids and prostaglandin biosynthesis after burn and endotoxin injury in rats. Retrieved on February 6, 2006.
    • IV Supplementation with gamma-linolenic acid increased serum GLA but did not increase the plasma percentage of arachidonic acid (rat study), decreased TXB2.
  16. ^ Belch, Jill JF and Alexander Hill (January 2000). Evening primrose oil and borage oil in rheumatologic conditions. Retrieved on February 12, 2006.
    • "DGLA itself cannot be converted to LTs but can form a 15-hydroxyl derivative that blocks the transformation of arachidonic acid to LTs. Increasing DGLA intake may allow DGLA to act as a competitive inhibitor of 2-series PGs and 4-series LTs and thus suppress inflammation."
  17. ^ a b Fan, Yang-Yi and Robert S. Chapkin (9 September 1998). "Importance of Dietary gamma -Linolenic Acid in Human Health and Nutrition". Journal of Nutrition 128 (9): 1411-1414. Retrieved on 2007-01-05.
    • "[D]ietary GLA increases the content of its elongase product, dihomo-gamma linolenic acid (DGLA), within cell membranes without concomitant changes in arachidonic acid (AA). Subsequently, upon stimulation, DGLA can be converted by inflammatory cells to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid and prostaglandin E1. This is noteworthy because these compounds possess both anti-inflammatory and antiproliferative properties."
  18. ^ Fischer S, Weber PC (Sep 1985). Thromboxane (TX)A3 and prostaglandin (PG)I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry.. Retrieved on February 10, 2006.
  19. ^ Prescott, Scott (1984). The effect of eicosapentaenoic acid on leukotriene B production by human neutrophils.. Retrieved on February 16, 2006.
  20. ^ Johnson MM, Swan DD, Surette ME, et al (1997). "Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans". J. Nutr. 127 (8): 1435–44. PMID 9237935.
  21. ^ Stone KJ, Willis AL, Hart WM, Kirtland SJ, Kernoff PB, McNicol GP. (1979 Feb). The metabolism of dihomo-gamma-linolenic acid in man.. Retrieved on February 15, 2006.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Essential_fatty_acid_interactions". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE